{"schema_version":"secwatch.filing_event.v1","accession":"0001370053-22-000049","form_type":"8-K","ticker":"ANAB","cik":"0001370053","company_name":"ANAPTYSBIO, INC","filed_at":"2022-08-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.535908+00:00","generated_at":"2026-06-23T18:29:27.258607+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Imsidolimab HARP Phase 2 fails to beat placebo in hidradenitis suppurativa; HS development halted","bullets":["Imsidolimab did not improve primary endpoint (AN count change) or HiSCR50 vs placebo at Week 16 in moderate-to-severe HS.","No imsidolimab-related serious/severe AEs; safety profile acceptable across arms.","Company discontinues imsidolimab development in HS; GEMINI-1 Phase 3 for GPP continues with data expected Q4 2023.","Plans to outlicense imsidolimab prior to potential FDA approval for GPP; focus on rosnilimab and ANB032 immune cell modulators.","Cash over $570M at Q2 end; AZURE Phase 2 rosnilimab data in alopecia areata anticipated Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001370053-22-000049","json":"https://secwatch.observer/filing/0001370053-22-000049.json","markdown":"https://secwatch.observer/filing/0001370053-22-000049.md","text":"https://secwatch.observer/filing/0001370053-22-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370053/000137005322000049/0001370053-22-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370053/000137005322000049/anab-20220831.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T18:29:27.258607+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}